Gilead starts trials of inhaled remdesivir for earlier-stage COVID-19The first healthy volunteers have started to receive doses of Gilead’s inhaled formulation of remdesivir, which it hopes Share XGilead starts trials of inhaled remdesivir for earlier-stage COVID-19https://pharmaphorum.com/news/gilead-starts-trials-of-inhaled-remdesivir-for-earlier-stage-covid-19/
ViiV gets FDA nod for Rukobia drug for older HIV patientsThe FDA has approved Rukobia, a first-in-class drug from ViiV Healthcare intended for older people with HIV, who Share XViiV gets FDA nod for Rukobia drug for older HIV patientshttps://pharmaphorum.com/news/viiv-gets-fda-nod-for-rukobia-drug-for-older-hiv-patients/
Atriva takes MEK inhibitor into phase 2 for COVID-19Atriva Therapeutics is starting a phase 2 trial of its MEK inhibitor ATR-002 in patients with coronavirus infections, Share XAtriva takes MEK inhibitor into phase 2 for COVID-19https://pharmaphorum.com/news/atriva-takes-mek-inhibitor-into-phase-2-for-covid-19/
Coronavirus news roundup 09/04/2020As the number of coronavirus cases in the world exceeds 1.4 million, the pharma industry is pushing to Share XCoronavirus news roundup 09/04/2020https://pharmaphorum.com/views-and-analysis/coronavirus-news-roundup-09-04-2020/
Synairgen doses first patients with COVID-19 drugUK biotech Synairgen has started dosing patients in its phase 2 trial of SNG001, an inhaled formulation of Share XSynairgen doses first patients with COVID-19 drughttps://pharmaphorum.com/news/synairgen-doses-first-patients-with-covid-19-drug/
Celltrion to develop coronavirus antibody and fast testSouth Korea’s Celltrion has joined the many pharma companies fighting the COVID-19 coronavirus outbreak, saying it is working Share XCelltrion to develop coronavirus antibody and fast testhttps://pharmaphorum.com/news/celltrion-antibody-and-fast-test/
